Progesterone gel - Juniper Pharmaceuticals

Drug Profile

Progesterone gel - Juniper Pharmaceuticals

Alternative Names: COL-1620; Crinone; Crinone 4%; Crinone 8%; OneCrinone; Prochieve; Prochieve 4%; Prochieve 8%; progesterone vaginal gel 4%; progesterone vaginal gel 8%

Latest Information Update: 22 Nov 2016

Price : $50

At a glance

  • Originator Columbia Laboratories
  • Developer Actavis; Allergan; Juniper Pharmaceuticals; Merck Serono
  • Class Hormonal contraceptives; Hormonal replacements; Infertility therapies; Pregnenediones; Small molecules
  • Mechanism of Action Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Amenorrhoea; Dysmenorrhoea; Female infertility; Menopausal syndrome; Menstruation disorders; Premenstrual syndrome
  • Discontinued Preterm labour

Most Recent Events

  • 22 Nov 2016 Juniper and Allergan enter into agreement to monetise future royalty payments for US sales of progesterone gel
  • 15 Nov 2016 Launched for Female infertility in Japan (Vaginal) before September 2016
  • 05 Jul 2016 Registered for Female infertility in Japan (Vaginal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top